Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria
Kidney International · 2026-09
DOI: 10.1016/j.kint.2026.08.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026-09. Verfasst von Matthew R Weir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. Electronic address: Mweir@som.um…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-controlled clinical trials, although its efficacy in patients with uHTN and CKD is not fully established. METHODS: This was a randomized, double-blind, placebo-controlled, crossover trial of lorundrostat (25 mg/day) added to a sodium-glucose cotransporter-2 inhibitor (SGLT2i) in adults with uHTN, CKD, and albuminuria on stable treatment with a renin-angiotensin-aldosterone system blocker. Participants were randomized to lorundrostat-placebo or placebo-lorundrostat in four-week treatment sequences with a four-week washout period. The primary end point was change in automated office systolic blood pressure (AOSBP). Other endpoints included change in urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). RESULTS: The 59 participants had a mean age of 64.6 years, mean body mass index of 33 kg/m2, and 76% had type 2 diabetes. At baseline, mean AOSBP was 149±10.4 mm Hg, geometric mean UACR (spot) was 516.8±2.51 mg/g, and cystatin C-eGFR was 43±15.0 mL/min per 1.73 m2. Least squares mean change in AOSBP was -1.8 mm Hg (95% Confidence Interval, -5.6, 2.1) with placebo and -9.3 mm Hg (-13.1, -5.4) with lorundrostat (placebo-adjusted, - 7.5 mm Hg (-12.3, -2.7)). Reduction in geometric mean of UACR was 30.5% (-41.0, -18.2) placebo-adjusted, 25.6% (-37.7, -11.2). eGFR decreased from 42.9±15.2 to 40.1±16.0 mL/min per 1.73 m2 with lorundrostat and from 42.9±15.1 to 42.1±15.8 mL/min per 1.73 m2 with placebo. Three participants discontinued treatment due to adverse events (hyperkalemia/CKD worsening, acute kidney injury, and retinal detachment). CONCLUSIONS: Lorundrostat added to SGLT2i reduced AOSBP and albuminuria in patients with uHTN and CKD and was associated with an acceptable safety profile. The observed reduction in albuminuria may suggest a potential cardiorenal benefit. However, longer-term studies are needed to determine whether these findings translate into durable kidney or cardiovascular outcomes. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT06150924.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. Electronic address: Mweir@som.umaryland.edu.
- Mineralys Therapeutics, Radnor, Pennsylvania, USA.
- Triad Internal Medicine, Asheboro, North Carolina, USA.
- Qwayresearch LLC, Hialeah, Florida, USA.
- Colorado Kidney Care, Denver, Colorado, USA.
- University of Washington, Seattle, Washington, USA.
Zitieren
APA
Weir, M. R., Bhaduri, S., Lee, K., Galvez, O., Kooienga, L., Kopjar, B., Novin, M., Rodman, D., & Explore-CKD Trial Group (2026). Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. Kidney International. https://doi.org/10.1016/j.kint.2026.08.021
Vancouver
Weir MR, Bhaduri S, Lee K, Galvez O, Kooienga L, Kopjar B, et al. Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria. Kidney International. 2026. doi:10.1016/j.kint.2026.08.021
BibTeX
@article{Weir2026,
author = {Weir, Matthew R and Bhaduri, Sarbani and Lee, Keung and Galvez, Oscar and Kooienga, Laura and Kopjar, Branko and Novin, Matthew and Rodman, David and Explore-CKD Trial Group, Explore-CKD Trial Group},
title = {Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria},
journal = {Kidney International},
year = {2026},
doi = {10.1016/j.kint.2026.08.021}
}
EUVIMED